Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...

The technology is said to “power” the t:slim X2 and Tandem Mobi, the company’s insulin delivery systems. Tandem Diabetes Care president and CEO John Sheridan said: “We have seen firsthand ...

1,2 Control-IQ powers both Tandem insulin delivery systems – the t:slim X2 and Tandem Mobi – to provide proven, best-in-class outcomes. Results from major studies of Tandem’s technology in type 1 ...

The next-generation Control-IQ+ algorithm, used to enable automated insulin delivery (AID) in conjunction with Tandem’s t:slim X2 and Mobi insulin pumps, was already approved for people with ...

Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Tandem Diabetes Care has secured a new FDA clearance ... the added “plus”—helps control the company’s automated t:slim X2 and Mobi insulin pumps with the help of a wearable continuous ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

the Company offered the Tandem Choice Program (Tandem Choice) to eligible t:slim X2 customers to provide a pathway to ownership of Tandem Mobi, for a fee when available. The Company offered ...

Tandem now offers the most robust ecosystem in insulin therapy management in the world. With our flagship t:slim and Tandem Mobi, we provide the greatest choice in pump platforms. We offer ...

SAN DIEGO, February 25, 2025--(BUSINESS WIRE)--Tandem Diabetes Care ... The trial compared use of a t:slim X2 pump with Control-IQ+ technology to a control group who continued their existing ...